Cutaneous CD30+ lymphoproliferative disorders: Expression of bcl-2 and proteins of the tumor necrosis factor receptor superfamily

Human Pathology

Volumn 29, Issue 11, 1998, Pages 1223-1230

  Paulli, Marco ^b   Berti, Emilio ^b   Boveri, Emanuela ^b   Kindl, Sandra ^b   Bonoldi, Emanuela ^b   Gambini, Claudio ^b   Rosso, Renato ^b   Borroni, Giovanni ^b   Straccapansa, Vincenzo ^b   Magrini, Umberto ^b   Decoteau, John E ^b   Krammer, Peter H ^b   Möller, Peter ^b   Kadin, Marshall E ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b NONE

Author keywords

Bcl 2; CD30+ cutaneous lymphoproliferative disorders; Fas (CD95)

Indexed keywords

CD27 ANTIGEN; CD30 ANTIGEN; CD40 ANTIGEN; FAS ANTIGEN; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR; PROTEIN BCL 2; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALE; PAPULOSIS; PROTEIN EXPRESSION; REED STERNBERG CELL; SKIN BIOPSY;

EID: 13144256770     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(98)90249-0     Document Type: Article

References (71)

1. Kadin ME: The spectrum of Ki-1+ cutaneous lymphomas, in van Vloten VA, Willemze R, Lange Vejlsgaard L, et al (eds): Cutaneous Lymphoma. Current Problems in Dermatology, vol 19. Basel, Karger, 1990, pp 132-143
2. Willemze R, Beljaards RC: Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders: A proposal for classification and guidelines for management and treatment. J Am Acad Dermatol 28:973-980, 1993
3. Paulli M, Berti E, Rosso R, et al: CD30/K1-1 positive lymphopro-liferative disorders of the skin: Clinicopathologic correlation and statistical analysis of 86 cases: A multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group. J Clin Oncol 13:1343-1354, 1995
4. Macaulay WL: Lymphomatoid papulosis: A continuing, self-healing eruption, clinically benign - histologically malignant. Arch Dermatol 97:23-30, 1968
5. Flynn KJ, Dehner LP, Gajl-Peczalska KJ, et al: Regressing atypical histiocytosis: A cutaneous proliferation of atypical neoplastic histiocytes with unexpectedly indolent biologic behavior. Cancer 49:959-970, 1982
6. Headington JT, Roth MS, Schnitzer B: Regressing atypical histiocytosis: A review and critical appraisal. Semin Diagn Pathol 4:28-37, 1987
7. Motley RJ, Jasani B, Ford AM, et al: Regressing atypical histiocytosis, a regressing cutaneous phase of Ki-1-positive anaplastic large cell lymphoma: Immunocytochemical, nucleic acid, and cytogenetic studies of a new case in view of current opinion. Cancer 70:476-483, 1992
8. Camisa C, Helm TN, Sexton C, et al: Ki-1-positive anaplastic large cell lymphoma can mimic benign dermatoses. J Am Acad Dermatol 29:696-700, 1993
9. Beljaards RC, Kaudewitz P, Berti E, et al: Primary cutaneous CD30-positive large cell lymphoma: Definition of a new type of cutaneous lymphoma with a favorable prognosis: An European multicenter study on 47 patients. Cancer 71:2097-2104, 1993
10. Kikuchi A, Nishikawa T: Apoptotic and proliferating cells in cutaneous lymphoproliferative diseases. Arch Dermatol 133:829-833, 1997
11. Fesus L: Apoptosis. Immunol Today 13:16-17, 1992
12. Buja LM, Eigenbrodt ML, Eigenbrodt EH: Apoptosis and necrosis: Basic types and mechanisms of cell death. Arch Pathol Lab Med 117:1208-1214, 1993
13. Cohen JJ: Apoptosis. Immunol Today 14:126-130, 1993
14. Ashwell JD, Berger NA, Cidlowski JA, et al: Coming to terms with death: apoptosis in cancer and immune development. Immunol Today 15:147-151, 1994
15. Farber E: Programmed cell death: Necrosis versus apoptosis. Mod Pathol 7:605-609, 1994
16. Williams GT: Apoptosis in the immune system. J Pathol 173:1-4, 1994
17. Smith CA, Farrah T, Goodwin RG: The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation and death. Cell 76:959-962, 1994
18. Gruss HJ, Boiani N, Williams DE, et al: Pleiotropic effects of CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 83:2045-2056, 1994
19. Gruss HJ, Dower SK: Tumor necrosis factor ligand superfamily: Involvement in the pathology of malignant lymphomas. Blood 85:3378-3404, 1995
20. Mallett S, Barclay AN: A new superfamily of cell surface proteins related to the nerve growth factor receptor. Immunol Today 12:220-223, 1991
21. Durkop H, Latza U, Hummel M, et al: Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 68:421-427, 1992
22. Smith CA, Gruss HJ, Davis T, et al: CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 73:1349-1360, 1993
23. Johnson D, Lanahan A, Buck CR, et al: Expression and structure of the human NGF receptor. Cell 47:545-554, 1986
24. Loetscher H, Pan Y-CE, Lahm HW, et al: Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 61:351-359, 1990
25. Schall TJ, Lewis M, Koller KJ, et al: Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 61:361-370, 1990
26. Smith CA, Davis T, Anderson D, et al: A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 248:1019-1023, 1990
27. Baens M, Chaffanet M, Cassiman JJ, et al: Construction and evaluation of a hncDNA library of human 12p transcribed sequences derived from a somatic cell hybrid. Genomics 16:214-218, 1993
28. Camerini D, Walz G, Loenen WAM, et al: The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family. J Immunol 147:3165-3169, 1991
29. Stamenkovic I, Clark EA, Seed B: A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J 8:1403-1410, 1989
30. Kwon BS, Weissman SM: cDNA sequences of two inducible T-cell genes. Proc Natl Acad Sci U S A 86:1963-1967, 1989
31. Mallett S, Fossum S, Barclay AN: Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes: A molecule related to nerve growth factor receptor. EMBO J 9:1063-1068, 1990
32. Itoh N, Yonehara S, Ishii A, et al: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233-243, 1991
33. Oehm A, Behrmann I, Falk W, et al: Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily: Sequence identity with the Fas antigen. J Biol Chem 267:10709-10715, 1992
34. Leithauser F, Dhein J, Mechterscheimer G, et al: Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis vactor receptor superfamily, in normal and neoplastic cells. Lab Invest 69:415-429, 1993
35. Hollenbaugh D, Grosmarie LS, Kullas CD, et al: The human T cell antigen gp39, a member of the tumor necrosis factor gene family, is a ligand for the CD40 receptor: Expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J 11:4313-4321, 1992
36. Bradshaw RA, Blundell TL, Lapatto R, et al: Nerve growth factor revisited. Trends Biochem Sci 18:48-52, 1993
37. Eide FF, Lowenstein DH, Reichardt LF: Neurotrophins and their receptors: Current concepts and implications for neurologic disease. Exp Neurol 121:200-214, 1993
38. Pennica D, Nedwin GE, Hayflick JS, et al: Human tumour necrosis factor: Precursor structure, expression and homology to lymphotoxin. Nature 312:724-729, 1984
39. Old LJ: Tumor necrosis factor (TNF). Science 230:630-632, 1985
40. Wang AM, Creasey AA, Ladner MB, et al: Molecular cloning of the complementary DNA for human tumor necrosis factor. Science 228:149-154, 1985
41. Beutler B, Cerami A: Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 320:584-588, 1986
42. Goodwin RG, Alderson MR, Smith CA, et al: Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell 73:447-456, 1993
43. Baum PR, Gayle RB, Ramsdell F, et al: Molecular characterization of murine and human OX40/OX40 ligand systems: Identification of a human OX40 ligand as the HTLV-1 regulated protein gp34. EMBO J 13:3992-4001, 1994
44. Godfrey WR, Fagnoni FF, Harara MA, et al: Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor. J Exp Med 180:757-762, 1994
45. Suda T, Takahashi T, Goldstein P, et al: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169-1178, 1993
46. Alderson MR, Tough TW, Davis-Smith T, et al: Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 181:71-77, 1995
47. Lynch DH, Watson ML, Alderson MR, et al: The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity 1:131-136, 1994
48. Takahashi T, Tanaka M, Brannan CI, et al: Generalized lymphoproliferative disease in mice caused by a point mutation in the Fas ligand. Cell 76:969-976, 1994
49. Itoh N, Tsujimoto Y, Nagata S: Effect of bcl-2 on Fas antigen-mediated cell death. J Immunol 151:621-627, 1993
50. Nagata S, Golstein P: The Fas death factor. Science 267:1449-1456, 1994
51. Dhein J, Daniel PT, Trauth BC, et al: Induction of apoptosis by nomoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell-surface antigens. J Immunol 149:3156-3173, 1992
52. Trauth BC, Klas C, Peters AMJ, et al: Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245:301-305, 1989
53. Dhein J, Walczak H, Baumler C, et al: Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373:438-441, 1995
54. Tsujimoto U, Croce CM: Analysis of the structure, transcripts and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Nati Acad Sci U S A 83:5214-5218, 1986
55. Hockenbery D, Nunez G, Milliman C, et al: bcl-2 is an inner mitochodrial membrane protein that blocks programmed cell death. Nature 348:334-336, 1990
56. Nunez G, London L, Hockenbery D, et al: Deregulated bcl-2 expression selectively prolongs survival of growth factor deprived hemopoietic cell lines. J Immunol 144:3602-3610, 1990
57. Korsmeyer SJ: bcl-2: A repressor of lymphocyte death. Immunol Today 13:285-288, 1992
58. Zutter M, Hockenberry D, Silverman GA, et al: Immunolocalization of the bcl-2 protein within hematopoietic neoplasms. Blood 78:1062-1068, 1991
59. Kondo E, Nakamura S, Onoue H, et al: Detection of bcl-2 protein and bcl-2 messenger RNA in normal and neoplastic lymphoid tissues by immunohistochemistry and in situ hybridization. Blood 80:2044-2051, 1992
60. Yoshino T, Kondo E, Cao L, et al: Inverse expression of bcl-2 protein and Fas antigen in lymphoblasts in peripheral lymph nodes and activated peripheral blood T and B lymphocytes. Blood 83:1856-1861, 1994
61. Kondo E, Yoshino T, Yamadori I, et al: Expression of bcl-2 protein and fas antigen in non-Hodgkin's lymphomas. Am J Pathol 14:330-337, 1994
62. Leong ASY, Milios J: Rapid immunoperoxidase staining of lymphocytes antigens using microwave irradiation. J Pathol 148:183-187, 1986
63. Hsu SM, Raine L, Fanger H: The use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase technique: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577-580, 1981
64. Cordell JL, Falini B, Erber WM, et al: Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 32:219-229, 1984
65. Wood GS, Freudenthal PS, Edinger A, et al: CD45 epitope mapping of human CD1a+ dendritic cells and peripheral blood dendritic cells. Am J Pathol 138:1451-1459, 1991
66. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1984
67. Willemze R, Kerl H, Sterry W, et al: EORTC classification for primary cutaneous lymphomas; A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 90:354-371, 1997
68. Cerroni L, Rieger E, Hodl S, et al: Clinicopathologic and immunologic features associated with transformation of mycosis fungoides to large cell lymphoma. Am J Surg Pathol 16:543-552, 1992
69. Ju ST, Panka DJ, Cul H, et al: Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373:444-448, 1995
70. Nguyen PL, Harris NL, Ritz J, et al: Expression of CD95 antigen and bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease. Am J Pathol 148:847-853, 1996
71. Dummer R, Michie SA, Kell D, et al: Expression of bcl-2 protein and Ki-67 nuclear proliferation antigen in benign and malignant cutaneous T-cell infiltrates. J Cutan Pathol 22:11-17, 1995